stoxline Quote Chart Rank Option Currency Glossary
  
Novo Nordisk A/S (NVO)
128.4  0.35 (0.27%)    03-28 16:00
Open: 128.39
High: 130.16
Volume: 3,500,469
  
Pre. Close: 128.05
Low: 127.79
Market Cap: 573,185(M)
Technical analysis
2024-03-28 4:53:17 PM
Short term     
Mid term     
Targets 6-month :  152.86 1-year :  161.51
Resists First :  130.88 Second :  138.27
Pivot price 131.19
Supports First :  118.91 Second :  98.93
MAs MA(5) :  128.73 MA(20) :  130.27
MA(100) :  111.85 MA(250) :  96.74
MACD MACD :  1.9 Signal :  2.9
%K %D K(14,3) :  21.2 D(3) :  29.5
RSI RSI(14): 52.4
52-week High :  138.27 Low :  75.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NVO ] has closed above bottom band by 18.5%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 130.26 - 130.87 130.87 - 131.45
Low: 126.19 - 126.91 126.91 - 127.59
Close: 127.24 - 128.35 128.35 - 129.39
Company Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Headline News

Thu, 28 Mar 2024
Novo Nordisk A/S (NYSE:NVO) Shares Up 1.1% - MarketBeat

Thu, 28 Mar 2024
How Much Does It Cost To Make Novo Nordisk's Ozempic? Shockingly Low Against $1,000 Price Tag, Study Show - Benzinga

Thu, 28 Mar 2024
Novo Nordisk Under Fire, Post-Ozempic Study - TipRanks.com - TipRanks

Thu, 28 Mar 2024
Novo Nordisk A/S (NYSE:NVO) is Traynor Capital Management Inc.'s 7th Largest Position - MarketBeat

Thu, 28 Mar 2024
Elevance, CVS Health Are First Medicare Insurers To Cover Novo Nordisk's Weight Loss Sensation Wegovy - C - Benzinga

Thu, 28 Mar 2024
Fort Washington Investment Advisors Inc. OH Purchases 100 Shares of Novo Nordisk A/S (NYSE:NVO) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4,460 (M)
Shares Float 3,190 (M)
Held by Insiders 0 (%)
Held by Institutions 9.2 (%)
Shares Short 4,670 (K)
Shares Short P.Month 7,520 (K)
Stock Financials
EPS 2.73
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 23.89
Profit Margin 36 %
Operating Margin 42.7 %
Return on Assets (ttm) 23.3 %
Return on Equity (ttm) 88 %
Qtrly Rev. Growth 37 %
Gross Profit (p.s.) 0
Sales Per Share 52.07
EBITDA (p.s.) 24.62
Qtrly Earnings Growth 63 %
Operating Cash Flow 108,910 (M)
Levered Free Cash Flow 54,100 (M)
Stock Valuations
PE Ratio 47.03
PEG Ratio 94.4
Price to Book value 5.37
Price to Sales 2.46
Price to Cash Flow 5.25
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android